User login
Key clinical point: Tumor necrosis factor (TNF)-α inhibitors effectively improved skin, nail, and joint symptoms and quality of life (QoL) in patients with nail psoriasis and concomitant psoriatic arthritis (PsA).
Major finding: During the first 3 months, nail psoriasis improved significantly along with improvements in the mean number of swollen joints (SJ), which reduced from 6.4 to 3.1, and the mean number of tender joints, which reduced from 10.8 to 6.4 (both P < .001). Low disease activity according to SJ status was achieved at month 24. QoL improved by 50% (P < .001) after 3 months with further improvements up to month 24.
Study details: Findings are from a noninterventional, prospective cohort study that evaluated effectiveness of 24 months of continuous therapy with adalimumab, etanercept, or infliximab in 100 adult patients with concomitant psoriasis, nail psoriasis, and PsA.
Disclosures: This study was sponsored by AbbVie Deutschland GmbH & Co. Two authors declared being employees and shareholders of AbbVie, and the other authors reported ties with several sources, including AbbVie Deutschland GmbH & Co.
Source: Kokolakis G et al. J Pers Med. 2021;11(11):1083 (Oct 25). Doi: 10.3390/jpm11111083.
Key clinical point: Tumor necrosis factor (TNF)-α inhibitors effectively improved skin, nail, and joint symptoms and quality of life (QoL) in patients with nail psoriasis and concomitant psoriatic arthritis (PsA).
Major finding: During the first 3 months, nail psoriasis improved significantly along with improvements in the mean number of swollen joints (SJ), which reduced from 6.4 to 3.1, and the mean number of tender joints, which reduced from 10.8 to 6.4 (both P < .001). Low disease activity according to SJ status was achieved at month 24. QoL improved by 50% (P < .001) after 3 months with further improvements up to month 24.
Study details: Findings are from a noninterventional, prospective cohort study that evaluated effectiveness of 24 months of continuous therapy with adalimumab, etanercept, or infliximab in 100 adult patients with concomitant psoriasis, nail psoriasis, and PsA.
Disclosures: This study was sponsored by AbbVie Deutschland GmbH & Co. Two authors declared being employees and shareholders of AbbVie, and the other authors reported ties with several sources, including AbbVie Deutschland GmbH & Co.
Source: Kokolakis G et al. J Pers Med. 2021;11(11):1083 (Oct 25). Doi: 10.3390/jpm11111083.
Key clinical point: Tumor necrosis factor (TNF)-α inhibitors effectively improved skin, nail, and joint symptoms and quality of life (QoL) in patients with nail psoriasis and concomitant psoriatic arthritis (PsA).
Major finding: During the first 3 months, nail psoriasis improved significantly along with improvements in the mean number of swollen joints (SJ), which reduced from 6.4 to 3.1, and the mean number of tender joints, which reduced from 10.8 to 6.4 (both P < .001). Low disease activity according to SJ status was achieved at month 24. QoL improved by 50% (P < .001) after 3 months with further improvements up to month 24.
Study details: Findings are from a noninterventional, prospective cohort study that evaluated effectiveness of 24 months of continuous therapy with adalimumab, etanercept, or infliximab in 100 adult patients with concomitant psoriasis, nail psoriasis, and PsA.
Disclosures: This study was sponsored by AbbVie Deutschland GmbH & Co. Two authors declared being employees and shareholders of AbbVie, and the other authors reported ties with several sources, including AbbVie Deutschland GmbH & Co.
Source: Kokolakis G et al. J Pers Med. 2021;11(11):1083 (Oct 25). Doi: 10.3390/jpm11111083.